Zhejiang Huahai Pharmaceutical Co Ltd: A Snapshot of Recent Performance and Market Position
Zhejiang Huahai Pharmaceutical Co., Ltd., a prominent player in the health care sector, has recently been in the spotlight due to its performance on the Shanghai Stock Exchange. As of August 17, 2025, the company’s stock closed at 20.78 CNH, reflecting a dynamic trading period. The stock has experienced significant fluctuations over the past year, reaching a 52-week high of 24.24 CNH on July 29, 2025, and a low of 13.49 CNH on April 8, 2025.
The company, headquartered in Linhai, China, specializes in the manufacturing and retailing of pharmaceutical products and medical raw materials. Zhejiang Huahai has established a strong global presence, exporting its products to numerous international markets. This global reach underscores its role as a key player in the pharmaceutical industry.
With a market capitalization of 311.7 billion CNH, Zhejiang Huahai Pharmaceutical Co. Ltd. demonstrates substantial financial strength. The company’s price-to-earnings ratio stands at 25.885, indicating investor confidence in its growth potential and profitability.
Founded in 2003, Zhejiang Huahai made its Initial Public Offering (IPO) on February 17, 2003, on the Shanghai Stock Exchange. Since then, it has grown significantly, maintaining its position as a leading pharmaceutical company in China and beyond.
For more detailed information about Zhejiang Huahai Pharmaceutical Co. Ltd. and its offerings, interested parties can visit the company’s website at www.huahaipharm.com .